The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review-Reference-Cited by-同舟云学术

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review

Published:2020-09-09 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Rozitis Eric,Johnson Ben,Cheng Yuen Yee,Lee Kenneth

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference104 articles.

1. Asbestos exposure and neoplasia.;Selikoff;JAMA.,1964

2. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group.;Husain;Arch Pathol Lab Med.,2018

3. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.;Baas;Ann Oncol.,2015

4. Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival.;Beebe-Dimmer;Clin Epidemiol.,2016

5. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.;Churg;Lung Cancer.,2018

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated DNA methylation analysis of peripheral blood from asbestos exposed populations and patients with malignant mesothelioma reveals novel methylation driver genes of diagnostic and prognostic relevance;Environmental Pollution;2024-12

2. Targeted Therapy in Mesotheliomas: Uphill All the Way;Cancers;2024-05-22

3. Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma;Current Medicinal Chemistry;2024-04-16

4. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma;Modern Pathology;2024-03

5. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues;BMJ Case Reports;2024-02